- Home
- CMPS vs SNDX Comparison
CMPS vs SNDX Comparison
Compare CMPS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | SNDX |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CMPS | SNDX |
|---|---|---|
| Price | $14.22 | $20.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $25.38 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $4.82 | $13.00 |
| 52 Week High | $15.40 | $25.59 |
Technical Indicators
Market Signals| Indicator | CMPS | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 49.23 |
| Support Level | $13.07 | $19.17 |
| Resistance Level | $14.87 | $22.40 |
| Average True Range (ATR) | 0.65 | 0.73 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 66.30 | 55.50 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.